Health Care·Pharmaceuticals·$6.1B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.31 | N/A | -10.71% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.31 | N/A | -10.71% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Overall, management acknowledged the difficulties faced in the current environment. They emphasized a focus on long-term strategies despite short-term setbacks.
Management expressed concerns about ongoing challenges in the market.
They highlighted the need for strategic adjustments moving forward.
Terns Pharmaceutical's earnings report indicates ongoing challenges, particularly reflected in the missed EPS target. The stock dropped 6.24% in response, suggesting investor concern over the company's current performance and lack of guidance. Without clear direction from management, investors may remain cautious in the near term.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
TERAWULF INC
May 15, 2023